Abstract:Objective To analyze the association between rtA181S mutation in the reverse-transcriptase(RT) domain of HBV and adefovir dipivoxil(ADV) resistance. Methods Incidence of rtA181S mutation of HBV RT region was screened and analyzed from large samples of chronically HBV-infected patients by direct sequencing. Clonal sequencing was performed and drug- resistance-associated mutations were analyzed from the serum of an ADV-refractory patient with chronic hepatitis B. pGEM-Teasy RT plasmid and pTriEx-HBV(C) plasmid were digested and ligated by the restriction enzyme(XhoⅠ/SphⅠ), and the 1.1-ploid genome length HBV recombinant plasmids harboring wild-type and three kinds of mutants in RT region were constructed. Then the replication-competent constructs were transiently transfected into the HepG2 cells. Five hours post-transfection, new medium containing different concentrations of ADV(0, 0.033, 0.100, 0.330, 1.000, 3.300 μmol/L) was supplemented every other day for 4 days. To analyze the phenotypic characteristics of the HBV mutants under the drug pressure, the supernatant was collected and HBV DNA production was quantitated using real-time PCR. Results A total of 12 000 serum samples of 9830 patients with chronic HBV infection were screened. rtA181S mutation was detected in 46 nucleos(t)ide analogues-treated patients. By contrast, signature ADV- resistance mutations rtN236T and A181V were detected in 653 patients. The rtA181S emerged either alone or in concomitance with other drug-resistance mutations. A follow-up patient developed virological and biochemical breakthrough after 19-month ADV monotherapy. At the time of sampling, rtA181S+N236T was detected by direct sequencing. Clonal sequence analysis of 24 clones showed that there were 11(45.83%) for wild-type, 6(25.00%) for rtN236T, 5(20.83%) for rtA181S, 1(4.16%) for rtA181V, and 1(4.16%) for rtA181S+N236T. The relative viral replication capacity of rtN236T, rtA181S and rtA181S+N236T mutants was 91. 35%, 29.90% and 68.53% that of the wild-type strain, respectively. Phenotypic resistance analysis showed that ADV suscep- tibility of mutants harboring rtN236T, rtA181S and rtA181S +N236T was 1/4.41, 1/3.05, and 1/5.43 that of the wild-type strain. Conclusions rtA181S is an ADV-resistance-associated mutation, which may cause the drug resistance solely or with other mutations in patients with chronic HBV infection. Compared to signature ADV-resistance mutation, rtA181S mutation is less resistant and less frequently detected in ADV-resistance patients.

Dissection of Mechanism for the Adefovir Dipivoxil Resistance in Chronic Hepatitis B Patients

Polymerase Mutations Rtn238r, Rtt240y and Rtn248h of Hepatitis B Virus Decrease Susceptibility to Adefovir

Efficacy of adefovir dipivoxil in treatment of chronic hepatitis B patients with lamivudine resistance

Screening and Identification of a Novel Adefovir Dipivoxil Resistance Associated Mutation, RTN236V, of HBV from a Large Cohort of HBV-Infected Patients

Analysis for phenotypic resistant characteristics of a novel mutation rtN236V in the reverse-transcriptase domain of hepatitis B virus isolated from an adefovir dipivoxil-refractory patient with chronic hepatitis B

Rte218g, a Novel Hepatitis B Virus Mutation with Resistance to Adefovir Dipivoxil in Patients with Chronic Hepatitis B

The Rate of Hepatitis B Virus Resistance to Adefovir Dipivoxil (ADV) and the Evolution of Hepatitis B Virus in Lamivudine-Resistant Chronic Hepatitis B Patients with ADV Monotherapy

The Rta181s Mutation of Hepatitis B Virus Primarily Confers Resistance to Adefovir Dipivoxil

The Relationship Between Resistance Mutants Induced by Adefovir(adv) and Hepatitis B Virus(hbv) Genotypes

[Research on Molecular Mechanism of Drug Resistance of Adefovir Dipivoxil].

rtA181S mutation in the reverse-transcriptase domain of HBV is associated with adefovir dipivoxil resistance

Adefovir resistance related mutations in reverse transcription region and their effect on the biological features of hepatitis B virus

Factors Influencing Inadequate or Suboptimal Response to Adefovir with or Without Genotypic Resistance.

Analysis of evolution and virological characteristics of rtI233V mutations in the hepatitis B virus reverse transcriptase domain

Application of PCR-RFLP in detection of adefovir dipivoxil resistance-associated mutations in hepatitis B virus

The relationship between HBV genotypes and antiviral efficacy of adefovir dipivoxil treatment

A Novel Baseline Hepatitis B Virus Sequencing-Based Strategy for Predicting Adefovir Antiviral Response

Tenofovir disoproxil fumarate vs adefovir dipivoxil in Chinese patients with chronic hepatitis B after 48 weeks: a randomized controlled trial.

Increased Occurrence of Mutant rtI233V of HBV in Patients Receiving Adefovir Therapy

Effect of Hepatitis B Virus Genotypes on the Efficacy of Adefovir Dipivoxil Antiviral Therapy

Adefovir dipivoxil for treatment of lamivudine-resistant patients with chronic hepatitis B:a multicenter clinical study